Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by ANALIAS00on Mar 09, 2021 11:50am
83 Views
Post# 32752827

RE:RE:RE:RE:NASH partnership

RE:RE:RE:RE:NASH partnership Yes you are right. But I really think they could be at the same place without the bought deal dont you think the same way ? And with that visibility increasing, they could have sign something better couple months later. But ok ok ok I get it. They were not willing to "gamble" and they may had to face something that we dont know. At some point I reconsidered TH's confidence for their own pipeline and products. But Paul, as any other CEO, seem very optimistic which is good of course. I know I keep going circle. But again, if you are so confident about your future, why not wait a little bit more for such deal ? Like if they really wanted to keep the SP low for another few months. Anyway... Soooooo lets be caution and wait for quarter after quarter's results and status/news about NASH and Oncology. Maybe one day we have the chance to understand what was the real rush and maybe we would have done the samething if were in their own shoes.
FredTheVoice wrote: Analia, we all need spring fast and sweet, still want you in my foursome......

Yes, I care about bad moves and impact on sharholders, I am one of them,

But still think that TH did the right move, giving some visibility with that bought deal. Sounds strange, but Th was out of the radar, now more visible, and cash in place to start both protocols.

Maybe not an "hole in one" before summer, but....

Cheers,

FTV.


<< Previous
Bullboard Posts
Next >>